Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
(Amendment) Notice of Amendment to “Notice of Tender Offer for Shares of TORII” Due to Submission of Amendment to Tender Offer Statement
Acceptance of a New Drug Application for Naldemedine, a Treatment for Opioid-Induced Constipation, in China
(Amendment) Notice of Amendment to “Notice of Tender Offer for Shares of TORII” and Public Notice Following Amendment to Tender Offer Statement
Amendments to Articles of Incorporation
Consolidaterd Financial Resauts for Fiscal Year 2024 (IFRS)
Financial results for the year ended March 31, 2025
FY2024 Finacial Results
Notice of the Execution of an Agreement for Company Split (Simplified Absorption-type Split) of the Pharmaceutical Business of Japan Tobacco Inc. and
Notice of Commencement of Tender Offer for Shares of TORII PHARMACEUTICAL CO., LTD. (Securities Code: 4551)
Notice of Revisions to Dividend Forecasts (Dividend Increase)
Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of COVID-19.
Notice of Transition to Company with Audit and Supervisory Committee and the Candidates for Directors After the Transition
Late-Breaking at CROI 2025: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylax
3rd Quarter of Fiscal 2024 Finacial Results
Consolidated Finacial Results for the Third Quarter of Fiscal Year 2024 (IFRS)
Financial Results for the 3rd Quarter of FY2024 Supplement
Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395
Acceptance of a New Drug Application for the COVID-19 Treatment, Ensitrelvir Fumaric Acid, in Taiwan and Conclusion of Government Stockpiling Contract
Shionogi Receives Award Through BARDA's RRPV to Advance Long-Acting Formulation of S-892216